Designer Drugs (The Wellness Center Pharmacy, Inc.), Chattanooga, TN

Is Designer Drugs (The Wellness Center Pharmacy, Inc.) registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.

Does Designer Drugs (The Wellness Center Pharmacy, Inc.) hold a Tennessee pharmacy license?

State pharmacy license records for Tennessee are not checked: the Department of Health’s license verification site did not respond to this index’s requests. This index reads only that state’s board actions. The Texas State Board of Pharmacy also lists nonresident license 31704 for DESIGNER DRUGS, CHATTANOOGA, TN, status Active, as of Nov 15, 2026. The California State Board of Pharmacy also lists nonresident license NRP 1779 for The Wellness Center Pharmacy Inc Dba Designer Drugs, Chattanooga, TN, status Active, as of Nov 6, 2026. The Illinois Department of Financial and Professional Regulation also lists nonresident license 054017803 for THE WELLNESS CENTER PHARMACY INC (dba DESIGNER DRUGS), CHATTANOOGA, TN, status ACTIVE, as of Nov 13, 2026. The Connecticut Department of Consumer Protection also lists nonresident license PCN.0002294 for DESIGNER DRUGS, CHATTANOOGA, TN, status ACTIVE (CURRENT), as of Nov 15, 2026. The Delaware Division of Professional Regulation also lists nonresident license A9-0001079 for The Wellness Center Pharmacy, Inc. (dba Designer Drugs), CHATTANOOGA, TN, status Active, as of Nov 10, 2026. The Michigan Department of Licensing and Regulatory Affairs also lists nonresident license 5301009702 for Designer Drugs, Chattanooga, TN, status Active, as of Nov 10, 2026.

Has Designer Drugs (The Wellness Center Pharmacy, Inc.) had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter close-out (Feb 6, 2019), 1 state referral letter (Feb 6, 2019) and 1 FMD-145 letter (Feb 6, 2019) for Designer Drugs (The Wellness Center Pharmacy, Inc.). State board actions: no Tennessee Board of Pharmacy action under this exact name and city was found in the Board of Pharmacy sections of the Tennessee Department of Health’s monthly Disciplinary Action Reports (actions dated January 2004 to April 2026) on Nov 15, 2026. The state referral and handoff letters above are FDA’s letters to the state, not board actions.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
The Wellness Center Pharmacy, Inc.; Designer Drugs
Location
Chattanooga, TN
Type as FDA labels it
503A
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
0
Warning letters on FDA’s actions page
0
Latest action on that page
Feb 6, 2019
FDA Data Dashboard inspections
2 inspections: 1 OAI, 1 VAI; 2 published Form 483s
Form 483 text on this page
1 Form 483, 13 observations
State board records
Not checked (license records); board actions matched: 0

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as The Wellness Center Pharmacy, Inc., (dba Designer Drugs), a 503A facility, with 3 dated actions.

Document
Feb 6, 2019State referral letterReferral Letter to the Tennessee Board of Pharmacy Issued 02/06/2019FDA copy (archived)
Feb 6, 2019FMD-145 letterFMD-145 Letter Issued 02/06/2019FDA copy (archived)
Feb 6, 2019Warning letter close-outWarning Letter Close Out Issued 02/06/2019Not linked by FDA

An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists The Wellness Center Pharmacy, Inc., Chattanooga, TN (FEI number 3004578635), matched to this page by exact name, city and state. It lists 2 inspections: 1 OAI, 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Dec 22, 2017Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30045786351037213
May 28, 2015Official Action Indicated (OAI)Drug Quality Assurance (Drugs)3004578635929306

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483 for this site has 13 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection May 18, 2015 to May 28, 2015: 13 observations

Firm on the cover
The Wellness Center Pharmacy, Inc., dba Designer Drugs, 7304 Jarnigan Rd, Chattanooga, TN 37421
FEI number
3004578635
Establishment type on the cover
Producer of Sterile Drug Products
FDA district office on the cover
404 BNA Dr., Bldg. 200, Ste. 500 Nashville, TN 37217-2597
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include adequate validation of the sterilization process.

Specifically,

a) Media fills performed for injectable drug products do not simulate the entire production process including but not limited t o: all process steps and manipulations, aseptic filling without terminal filtration, and all container/closure systems used for d rug products. Additionally, media fills do not include a challenge of worst case conditions including but not limited to: duration of aseptic processing and representative batch size.

b) Integrity testing specifications set by your firm for the Supor 25 and 32 mm syringe filters (0.22 µm) have not been verified by the manufacturer or otherwise validated. These filters are used as sterilizing filters in production of injectable drug products.

c) Sterilization cycles using the Tuttnauer Tabletop Autoclave Model 2340 have not been validated for terminally sterilized finished drug products. ...

Read the full 483 (PDF on fda.gov)

Observation 2

Clothing of personnel engaged in the manufacturing, processing, and packing of drug products is not appropriate for the duties they perform.

Specifically, polypropylene isolation barrier gowns, earloop masks, and bouffant caps used for aseptic processing in the Laminar Air Flow Hood (LAFH) (ISO 5 area) are not sterile. Additionally, gowning used for processing in the ISO 5 area does not provide for adequate coverage of the operator. The gowning does not cover the operator's skin on the face and neck and it does not completely cover the operator's clothing. Portions of the operator's backside and lower legs are left uncovered bv the isolation barrier gown.

Observation 3

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the equipment to produce aseptic conditions.

Specifically,

a) Sodium Hypochlorite 0.1 % solution used to clean the LAFH (ISO 5 area) is not sterile. Additionally, the ISO 5 area is not periodically cleaned with a sporicide that has been demonstrated to be effective.

b) Blue Shop Towels used for cleaning the LAFH (ISO 5 area) are not sterile.

Observation 4

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically,

a) Environmental monitoring of the LAFH (ISO 5 area) including surface, air, and personnel is not performed each day drug products are produced using the LAFH. Currently, surface and personnel monitoring is only performed every two weeks . Also, surface samples taken from the LAFH on 05/18/2015 were taken prior to production immediately after cleaning inste ad of after production activities. Additionally, non-viable particulate monitoring is only performed every six months during the certification of the LAFH and clean room.

b) The last qualification of the LAFH (Baker model EG-4252 and serial number E-42081) on 01/26/2015 did not include passive viable air sampling. It has been more than 6 months since passive viable air sampling in LAFH has been performed.

c) Raw data for dynamic smoke studies performed in the LAFH (ISO 5 area) were not documented and retained.

Observation 5

Equipment for adequate control over air pressure and micro-organisms is not provided when appropriate for the manufacture, processing, packing or holding of a drug product.

Specifically,

The LAFH (ISO 5 area) is not equipped with an air pressure gauge for monitoring pressure differentials. Also, air pressure , differentials of the Buffer (IV) Room (ISO 7 area) and the Anteroom (ISO 8 area) are not continuously monitored during production of drug products. Currently, pressure differentials are only checked once a day. Additionally, the pressure reading of the Buffer (IV) Room was observed to be 0.03 inches of water immediately after the sterile filtration of Tri-Mix Lot# 05182015@15. Your firm's pressure differential specification is 0.05 inches of water or greater.

Observation 6

Aseptic processing areas are deficient regarding air supply that is filtered through high-efficiency particulate air filters under positive pressure.

Specifically,

a) The sterile prep area where drug components are weighed, dispensed, and mixed prior to aseptic mixing and filtration is not environmentally controlled. There are no physical barriers to separate the area from the non-sterile prep areas. The air system for the sterile prep area is shared with the rest of the facility and is not appropriately filtered. The ceiling and floors in the sterile prep area are not constructed ofreadily cleanable materials. Additionally, access to the sterile prep area is not restricted. The area is equipped with a door which opens directly to the retail lobby and entry through this door is not restricted.

b) Hormone Replacement Pellets are prepared in a room, prior to terminal sterilization, which is not environmentally controlled. The air system for the sterile prep area is shared with the rest of the facility and is not appropriately filtered. The ceiling and floors in the sterile prep area are not constructed ofreadily cleanable materials. ...

Read the full 483 (PDF on fda.gov)

Observation 7

Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design and suitably

located to facilitate operations ·for its cleaning and maintenance.

Specifically,

a) An office phone with handset is mounted to the wall in the Buffer (IV) Room (ISO 7 area).

b) A chair located in the Buffer (IV) Room used by technicians during aseptic operations in the LAFH (ISO 5 area) is not

constructed of materials that can be readily sanitized.

c) There is no line of demarcation in the anteroom to separate the clean side from the dirty side. The anteroom is used for

hand washing and gowning prior to entering the Buffer (IV) Room (ISO 7).

I

Observation 8

The calibration of instruments, apparatus, and gauges is not done at suitable intervals .

Specifically,

a) The Millipore pressure gauge identified as "Jan 20 I 0 8978 8920" used to perform post filtration integrity testing of all

sterilizing filters has not been calibrated.

b) Thermometers used in the QL 140E and Boeke! model 13200 incubators have not been calibrated. The QL 140E and Boeke! model 13200 incubators are used for the incubation of environmental samples and finished drug product sterility and endotoxin samples.

Observation 9

Each batch of drug product required to be free of objectionable microorganisms is not tested through appropriate laboratory testing.

Specifically,

Sterility testing per your firm's procedure "9. I I 0 Sterile Compounding Finished Preparation Testing" is only required on lots consisting of25 or more units that are exposed longer than 12 hours at temperatures of 2-8 degrees Celsius and longer than six hours at warmer temperatures. Additionally, endotoxin testing is not performed on Hormone Replacement Pellets.

Observation 10

Testing and release of drug product for distribution do not include appropriate laboratory determination ofsatisfactory conformance to the final specifications and identity and strength ofeach .active ingredient prior to release.

Specifically,

Potency testing is not performed on every lot of sterile drug product produced by your firm. Potency testing is at the discretion of the Pharmacist-in-charge according to your firm's procedure "9.110 Sterile Compounding Finished Preparation Testing."

Observation 11

There is no written testing program designed to assess the stability characteristics of drug products.

Specifically,

Stability testing performed to extend Beyond Use Dates (BUDS) of sterile drug products up to 270 days did not include sterility testing over the the beyond use period. Also, stability studies for preservative containing sterile products did not in clude testing of the antimicrobial effectiveness of the preservatives over the beyond use period.

Observation 12

Laboratory records do not include complete data derived from all tests, examinations and assay necessary to assure compliance with established specifications and standards.

Specifically,

Temperatures of the QL 140E and Boekel model 13200 incubators are not continuously monitored or documented during incubation of environmental samples and finished drug product sterility and endotoxin samples.

Observation 13

Each component is not tested for conformity with all appropriate written specifications for purity, strength, and quality.

Specifically, compressed nitrogen used as a blanket/overlay gas in sterile filtered drug products is industrial grade nitorgen. No testing or certificate of analysis in lieu of testing was obtained prior to the use ofthis industrial grade nitrogen gas in sterile drug production.

Linked 483s whose text is not shown

State board of pharmacy records

State pharmacy license records for Tennessee are not checked: the Department of Health’s license verification site did not respond to this index’s requests. This index reads only that state’s board actions. Board actions source.

What this covers: Board of Pharmacy actions against pharmacies and other business licensees from the Department of Health’s monthly Disciplinary Action Reports (260 of 263 monthly reports read, 137 with a Board of Pharmacy section). The reports list final board actions for the month named, worded as the department gives them; each action is dated by its report month. Actions against individual pharmacists and technicians are not copied. An entry that gives a city but no state is read as a Tennessee address, as the reports write them. Tennessee pharmacy licenses are not checked. Actions in the data are dated January 2004 to April 2026.

Nonresident licenses in other states

These boards list a nonresident license whose record names this pharmacy’s own name, city and state.

Texas State Board of Pharmacy, file dated Nov 15, 2026 (Texas).

LicenseType as the board gives itName on the board recordLocationStatusPrior disciplinary orders (file flag)
31704Non Resident Sterile CompoundingDESIGNER DRUGSCHATTANOOGA, TNActiveNo

California State Board of Pharmacy, file dated Nov 6, 2026 (California).

LicenseType as the board gives itName on the board recordLocationStatus
NRP 1779Non Resident PharmacyThe Wellness Center Pharmacy Inc Dba Designer DrugsChattanooga, TNActive

Illinois Department of Financial and Professional Regulation, file dated Nov 13, 2026 (Illinois).

LicenseType as the board gives itName on the board recordLocationStatus
054017803LICENSED PHARMACYTHE WELLNESS CENTER PHARMACY INC (dba DESIGNER DRUGS)CHATTANOOGA, TNACTIVE

Connecticut Department of Consumer Protection, file dated Nov 15, 2026 (Connecticut).

LicenseType as the board gives itName on the board recordLocationStatus
PCN.0002294NONRESIDENT PHARMACYDESIGNER DRUGSCHATTANOOGA, TNACTIVE (CURRENT)

Delaware Division of Professional Regulation, file dated Nov 10, 2026 (Delaware).

LicenseType as the board gives itName on the board recordLocationStatus
A9-0001079Non Resident PharmacyThe Wellness Center Pharmacy, Inc. (dba Designer Drugs)CHATTANOOGA, TNActive

Michigan Department of Licensing and Regulatory Affairs, file dated Nov 10, 2026 (Michigan).

LicenseType as the board gives itName on the board recordLocationStatus
5301009702PharmacyDesigner DrugsChattanooga, TNActive

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.